Dominick M. Lamonica, MD

Specialty: Nuclear Medicine
Department of Diagnostic and Interventional Radiology
Interim Director of Nuclear Medicine and Theranostics

 Request an Appointment
Locations

Roswell Park Main Campus
1-800-ROSWELL (1-800-767-9355)

Dr. Lamonica is a Buffalo Spree Top Doctor! Top Doctors 2024 See all of our physicians who made this year's list.

Cancers Treated:

Bladder Carcinoid Chronic Lymphocytic Leukemia Esophageal Gallbladder & Bile Duct Lymphoma Multiple Myeloma Neuroendocrine Tumors Non-Hodgkin Lymphoma Ovarian Pancreatic Penile Prostate Testicular Thyroid Parathyroid Urethral

Research Interests:

  • Positron emission tomography (PET) of lymphoma
  • Radioimmumotherapy of lymphoma and inoperable pancreatic carcinoma

Positions

Roswell Park Comprehensive Cancer Center

  • Associate Professor of Oncology
  • Interim Director of Nuclear Medicine and Theranostics
  • Department of Diagnostic and Interventional Radiology

Jacobs School of Medicine and Biomedical Sciences, State University of New York at Buffalo

  • Associate Professor of Radiology and Clinical Nuclear Medicine, Department of Nuclear Medicine

Background

Education and Training

  • Mt. Sinai School of Medicine (MD) City University of New York New York, NY

Residency

  • State University of New York at Stony Brook (Internal Medicine) Stony Brook, NY
  • State University of New York at Stony Brook (Nuclear Medicine) Stony Brook, NY

Fellowship

  • State University of New York at Buffalo (Nuclear Medicine) Buffalo, NY

Board Certification

  • Internal Medicine, American Board of Internal Medicine
  • Nuclear Medicine, American Board of Nuclear Medicine

Publications

  • S Sundaram, M Jizzini, D Lamonica et al. Utility of bone marrow aspirate and biopsy in staging of patients with T-cell lymphoma in the PET-Era – tissue remains the issue. Leukemia and Lymphoma DOI: 10.1080/10428194.2020.1798950
  • D Lamonica, DA Graf, MC Munteanu, MS Czuczman. 18F-Fluorodeoxyglucose (FDG) PET for Measurement of Response and Prediction of Outcome to Relapsed/Refractory Mantle Cell Lymphoma (MCL) Therapy with Bendamustine-Rituximab (BR). J Nucl Med 58 (1), 62-68. 2016 Jul 28
  • M Czuczman, A Goy, D Lamonica, D Graf, M Munteanu, R van der Jagt. Phase II study of bendamustine combined with rituximab in relapsed/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings. 2015 Annals of Hematology 94(12), pp 2025-2032
  • KJ Mylam, L Kostakoglu, M Hutchings, M Coleman, D Lamonica, MS Czuczman et al 18F-fluorodeoxyglucose positron emission tomography/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: Results of a Nordic /US intergroup study. Leukemia and Lymphoma 2015 56 (7), 2005-2012
  • Bush E, Lamonica D, O'Connor T. Sarcoidosis mimicking metastatic breast cancer. Breast journal 2011;175:533-535
  • Yao S, Smiley SL, West K, Lamonica D, Battiwalla M, McCarthy PL, Hahn T. Accelerated bone mineral density loss occurs with similar incidence and severity, but with different risk factors, after autologous versus allogeneic hematopoietic cell transplantation. Biology of blood and marrow transplantation2010; 168:1130-1137
  • May KS , Lamonica D , Nava HR , Gibbs JF , Yendamuri SS , Nwogu CE , Iyer RV , Yap JC , Warner JC , Russo RC , Malhotra HK , Flaherty L , Wilding GE , Chandrasekhar R , Khushalani NI , Yang GY , Thomas Jr CR.Association of Technetium(99m) MAG-3 renal scintigraphy with change in creatinine clearance following chemoradiation to the abdomen in patients with gastrointestinal malignancies. Journal of gastrointestinal oncology 2010; 11:7-15
  • Michael Turtle R, Loree TR, Lydiatt WM, McCaffrey J, Olson Jr JA, Parks L, Ridge JA, Shah JP, Sherman SI, Waguespack SG, Wang TN, Lamonica DM, Kopp P, Kloos RT, Ball DW, Byrd D, Daniels GH, Dilawari RA, Doherty GM, Duh Q-Y, Ehya H, Farrar WB, Haddad RI, Kandeel F, Wirth LJ. Medullary carcinoma. Journal of the National Comprehensive Cancer Network : JNCCN 2010; 85:512-530
  • Tuttle RM , Lydiatt WM , McCaffrey JC , Olson JA , Parks L , Ridge JA , Shah JP , Sherman SI , Sturgeon C , Waguespack SG , Wang TN , Loree TR , Lamonica DM , Kopp P , Ball DW , Byrd D , Dilawari RA , Doherty GM , Duh QY , Ehya H , Farrar WB , Haddad RI , Kandeel F , Kloos RT , Wirth LJ. Thyroid carcinoma.Journal of the National Comprehensive Cancer Network : JNCCN 2010; 811:1228-1274
  • Yao S, Padmanabhan S, Battiwalla M, Smiley S, Lamonica D, Syta M, Paplham P, Brown K, Roy DM, Dunford LM, McCarthy PL, Hahn T. High prevalence of early-onset osteopenia/osteoporosis after allogeneic stem cell transplantation and improvement after bisphosphonate therapy. Bone marrow transplantation 2008; 414:393-398
  • Khalaf M, Abdel-Nabi H, Baker J, Shao Y, Lamonica D, Gona J. Relation between nodule size and 18F-FDG-PET SUV for malignant and benign pulmonary nodules. Journal of hematology and oncology 2008;1:13
  • Klippenstein DL, Lamonica DM. Preoperative imaging for metastasectomy. Surgical oncology clinics of North America 2007; 163:471-492, vii
  • Sherman SI, Lamonica DM, Loree TR, Lydiatt WM, McCaffrey J, Olson JA Jr, Ridge JA, Shah JP, Sisson JC, Tuttle RM, Urist MM, Kopp P, Kloos RT, Angelos P, Ball DW, Byrd D, Clark OH, Daniels GH, Dilawari RA, Ehya H, Farrar WB, Gagel RF, Kandeel F, National Comprehensive Cancer Network Thyroid Carcinoma Panel. Thyroid carcinoma. Journal of the National Comprehensive Cancer Network : JNCCN 2007;56:568-621